Lupin Limited reported a robust performance for the quarter ended March 31, 2026. The company achieved a 33% year-on-year growth in sales to INR 73,919 million. Driven by strong momentum in key markets and complex product launches, the company reported a net income of INR 14,604 million, reflecting an 89% year-on-year increase. EBITDA margins remained healthy at 29.4%, underscoring the company’s continued operational strength and strategic focus on complex generics and biosimilars.
Financial Highlights
For the fourth quarter of FY26, Lupin posted consolidated net sales of INR 73,919 million, a significant 33% increase compared to the same period last year. The company’s profitability saw substantial gains, with EBITDA reaching INR 21,711 million, up 68% year-on-year. Net income for the quarter stood at INR 14,604 million, marking an 89% increase over Q4 FY25.
Geographic Performance
Lupin’s global footprint continues to drive growth, led by North America, which recorded sales of INR 35,145 million, a 55% year-on-year increase. The domestic India business also showed solid performance, contributing INR 19,082 million in sales, up 12% year-on-year. Other international regions also saw positive growth, with EMEA growing 19%, LATAM soaring by 75%, and APAC rising 9%.
Strategic Milestones and Product Launches
The company successfully launched key products in the US, including Dapagliflozin Tabs (gFarxiga®) and received a tentative approval for Sugammadex Inj (gBridion®). Business development efforts included the acquisition of VISUfarma B.V. to expand its specialty pharma presence in Europe and an agreement with Galenicum for Semaglutide in 23 countries. Additionally, the company received the European Commission’s approval for its biosimilar Ranibizumab (Ranluspec™).
Operational Excellence and Quality
Lupin continues to pivot its R&D efforts toward complex generics and biosimilars. The company has made significant strides in regulatory compliance, with several manufacturing sites receiving successful US FDA inspections and Establishment Inspection Reports (EIR). Looking ahead, Lupin maintains a strong pipeline of 45+ injectables and 20+ inhalation products, with a clear goal to launch 20+ new products in the Indian market in FY27.
Source: BSE
